Literature DB >> 8593023

In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.

K P Giron1, M E Gross, D M Musher, T W Williams, R A Tharappel.   

Abstract

Adding rifampin to penicillin or l-ofloxacin diminished the rate at which these antibiotics killed 21 clinical isolates isolates of Streptococcus pneumoniae in vitro. A less pronounced inhibitory effect was observed when rifampin was added to ceftriaxone. Synergy was not observed for any bacterial isolate. The in vitro demonstration of indifference or antagonism using these antibiotic combinations argues against the empirical addition of rifampin to beta-lactams or fluoroquinolones in treating serious pneumococcal infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593023      PMCID: PMC163033          DOI: 10.1128/AAC.39.12.2798

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Antimicrobial activities of beta-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci.

Authors:  M E Gross; K P Giron; J D Septimus; E O Mason; D M Musher
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

2.  Antistaphylococcal activity of rifampin with other antibiotics.

Authors:  S H Zinner; H Lagast; J Klastersky
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

3.  Interaction between vancomycin and rifampin against Staphylococcus aureus.

Authors:  C Watanakunakorn; J C Guerriero
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

4.  Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection.

Authors:  R M Locksley; M L Cohen; T C Quinn; L S Tompkins; M B Coyle; J M Kirihara; G W Counts
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

5.  Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies.

Authors:  G L Archer; J L Johnston; G J Vazquez; H B Haywood
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

6.  Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis.

Authors:  A W Karchmer; G L Archer; W E Dismukes
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

7.  Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin.

Authors:  C W Norden; J Fierer; R E Bryant
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

8.  Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents.

Authors:  C W Norden
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

9.  Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits.

Authors:  O Zak; W M Scheld; M A Sande
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

10.  Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections.

Authors:  P Van der Auwera; F Meunier-Carpentier; J Klastersky
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug
View more
  5 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

Authors:  K P Klugman; T Capper; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

3.  Infected abdominal aortic aneurysm due to penicillin-, ceftriaxone-, and cefotaxime-resistant Streptococcus pneumoniae.

Authors:  W E Albrecht; C J Papasian; D M Bamberger; R Fiorella; S W Riddell
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

Review 4.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

5.  Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Doménech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-17       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.